The Challenge of CMC Regulatory Compliance for Biopharmaceuticals

Éditeur :

Springer

Paru le : 2023-06-15

Each year for the past three years, there have been about 50 new molecular medicines approved by the United States Food & Drug Administration (FDA), of which approximately 25% were new biopharmaceuticals. Over 200 recombinant proteins, monoclonal antibodies, antibody drug conjugates, fusion proteins...
Voir tout
Ce livre est accessible aux handicaps Voir les informations d'accessibilité
Ebook téléchargement , DRM LCP 🛈 DRM Adobe 🛈
Compatible lecture en ligne (streaming)
137,14
Ajouter à ma liste d'envies
Téléchargement immédiat
Dès validation de votre commande
Image Louise Reader présentation

Louise Reader

Lisez ce titre sur l'application Louise Reader.

À propos

Auteur

Éditeur

Collection
n.c

Parution
2023-06-15

Pages
573 pages

EAN papier
9783031319082

Auteur(s) du livre


John Geigert, Ph.D., RAC is President of BioPharmaceutical Quality Solutions, in San Diego, California. He has over 40 years of experience within the biopharmaceutical industry developing Chemistry, Manufacturing & Controls (CMC) regulatory compliant strategies for recombinant proteins, monoclonal antibodies, biosimilars, gene therapy vectors, and cell-based medicines. Dr. Geigert has 10 years Executive Management experience as Vice President, Quality & Executive Officer at IDEC Pharmaceuticals, and Vice President, Quality at Immunex.  He now has served for 20 years as an international independent CMC regulatory compliance consultant.  He is a past chair of the PDA Biopharmaceutical Advisory Board.  Dr. Geigert is also the author of the book, The Challenge of CMC Regulatory Compliance for Biopharmaceuticals 3rd Edition (May 2019). 

Caractéristiques détaillées - droits

EAN PDF
9783031319099
Prix
137,14 €
Nombre pages copiables
5
Nombre pages imprimables
57
Taille du fichier
19773 Ko
EAN EPUB
9783031319099
Prix
137,14 €
Nombre pages copiables
5
Nombre pages imprimables
57
Taille du fichier
61921 Ko

Suggestions personnalisées